Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kids B-LONG: rFIXFc in Pediatric Hemophilia B
NCT01440946Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2012
- Primary completion
- Nov 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of eftrenonacog alfa in hemophilia B (HB), sponsored by Sanofi. Primary endpoint: Occurrence of Factor IX (FIX) Inhibitor Development at 50 weeks. Started Jun 2012; status: completed.
02
Drugs
eftrenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01440946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440946.